ITUS - ITUS Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.45
+0.08 (+2.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.37
Open3.38
Bid3.10 x 400
Ask3.75 x 500
Day's Range3.37 - 3.49
52 Week Range0.60 - 6.43
Volume98,466
Avg. Volume116,457
Market Cap63.843M
Beta1.41
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.12
Trade prices are not sourced from all markets
  • ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer
    PR Newswire16 days ago

    ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

    SAN JOSE, Calif. , July 6, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that due to the significance of positive results as well as strong commercial interest, it has selected breast ...

  • ITUS to Ring the NASDAQ Closing Bell on July 5th
    PR Newswire23 days ago

    ITUS to Ring the NASDAQ Closing Bell on July 5th

    ITUS recently announced that the CAR-T therapy for ovarian cancer, being developed in collaboration with The Moffitt Cancer Center, is roughly one year ahead of its original development timeline, and the Company anticipates a pre-IND meeting with the US FDA in the October/November timeframe.  Assuming the FDA does not require significant additional animal studies, the IND application could be filed as soon as Q1 of 2019 with human trials beginning as early as the first half of 2019. The event can be viewed live by visiting https://new.livestream.com/nasdaq/live.

  • ITUS Accelerates Schedule for its CAR T Therapy and Provides Update
    PR Newswire26 days ago

    ITUS Accelerates Schedule for its CAR T Therapy and Provides Update

    SAN JOSE, Calif., June 26, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today provided a status update and accelerated development timeline for its CAR T therapy for Ovarian Cancer, which is in development with Moffitt Cancer Center. ITUS initiated a Cooperative R&D Agreement (CRADA) with Moffitt to advance a proprietary CAR T therapy for ovarian cancer in November 2017.  The study is led by Jose Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt.  The aim of this CRADA is to complete the pre-clinical studies necessary for the submission of an IND application to the FDA, seeking approval to test the therapy in human patients.  The previous goal for IND submission was the end of 2019 or early 2020, now it has been accelerated dramatically.

  • ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer
    PR Newswirelast month

    ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

    SAN JOSE, Calif. , June 13, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has chosen prostate cancer as the first commercial focus for its Cchek™, non-invasive liquid biopsy ...

  • ACCESSWIRElast month

    ITUS Corp. (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy

    CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. At the helm of innovation in the cancer diagnostics and immunotherapy markets, we find ITUS Corp. (NASDAQ: ITUS).

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Fiserv and Three More Business Services Stocks

    Research reports have been issued by WallStEquities.com on Fiserv Inc. (NASDAQ: FISV), FleetCor Technologies Inc. (NYSE: FLT), Genpact Ltd (NYSE: G), and ITUS Corp. (NASDAQ: ITUS). Companies in the Business Services sector provide support services, such as office administration, hiring and placing of personnel, security services, travel arrangement, cleaning, and waste disposal, to businesses.

  • Who Really Owns ITUS Corporation (NASDAQ:ITUS)?
    Simply Wall St.3 months ago

    Who Really Owns ITUS Corporation (NASDAQ:ITUS)?

    Today, I will be analyzing ITUS Corporation’s (NASDAQ:ITUS) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...

  • ACCESSWIRE3 months ago

    ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 3 rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8 th at ...

  • PR Newswire4 months ago

    ITUS Presentation to Special Meeting of Stockholders

    SAN JOSE, Calif., April 2, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website.  It can be viewed at http://ir.ituscorp.com/corporate-presentation.

  • ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
    PR Newswire4 months ago

    ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

    SAN JOSE, Calif., March, 27, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.

  • ITUS Announces Issuance of Second Key Cancer Detection Technology Patent
    PR Newswire4 months ago

    ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

    SAN JOSE, Calif. , March 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent ...

  • Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry
    Simply Wall St.4 months ago

    Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry

    When ITUS Corporation (NASDAQ:ITUS) released its most recent earnings update (31 January 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting
    PR Newswire4 months ago

    ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting

    SAN JOSE, Calif. , March 16, 2018 /PRNewswire/ --   ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting ...

  • ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting
    PR Newswire4 months ago

    ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

    SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois.  The meeting will be held April 14-18, 2018 and will be attended by world leading experts across the field of cancer research.  All abstracts will be viewable by registered attendees beginning March 14, 2018.  To receive a copy of the presentation, please email your request to AACR-2018@ITUScorp.com starting April 19, 2018 and include your name, title, and contact information. The presentation will focus on ITUS' proprietary Cchek™ platform featuring new data and insights into this early cancer detection technology.  Cchek™ combines the immunophenotyping of white blood cells using flow cytometry with a proprietary neural network, a type of artificial intelligence (AI), to detect the presence of solid tumors from a blood sample.  Identifying and measuring circulating myeloid-derived suppressor cells (MDSCs), a group of immunosuppressive white blood cells, is the foundation of this technology.

  • ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
    PR Newswire4 months ago

    ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

    SAN JOSE, Calif. , March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop , Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018 , ...

  • ITUS Corporation Forms Alliance with Serametrix Corporation
    PR Newswire5 months ago

    ITUS Corporation Forms Alliance with Serametrix Corporation

    SAN JOSE, Calif., March 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's substantial expertise in immune monitoring assays.  Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.

  • ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations
    PR Newswire5 months ago

    ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations

    SAN JOSE, Calif., Feb. 7, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that its presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," has been accepted for presentation at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology. The presentation will focus on ITUS' proprietary Cchek™ platform which utilizes immuno-profiling via Flow Cytometry and Artificial Intelligence to enable the detection of solid tumors from a blood sample.

  • ACCESSWIRE6 months ago

    Blog Exposure - ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

    Stock Monitor: Alliance Data Systems Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS ).If ...

  • Business Wire6 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of ITUS Corporation

    Levi & Korsinsky announces it has commenced an investigation of ITUS Corporation concerning possible breaches of fiduciary duty. To obtain additional information

  • ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium
    PR Newswire6 months ago

    ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

    Statistics clearly show that when cancer is detected early (Stage I or II), the chances of long term survival are often greater than 95%, or even 100% in some cases. However, if the cancer is detected late (Stage III or IV), the probability of long term survival declines to levels as low as 10%.  Understandably, there has been tremendous interest from the scientific and investment community in the development of techniques for early cancer detection.  ITUS, one of the few publicly traded companies operating in this arena, utilizes a proprietary technique to monitor changes in a patient's immune system driven by the presence of a tumor. Studies over the past decade have demonstrated that there is a dynamic interaction between a patient's immune system and the existence of a tumor.

  • Is ITUS Corporation (NASDAQ:ITUS) Thriving Or Barely Surviving In The Tech Sector?
    Simply Wall St.6 months ago

    Is ITUS Corporation (NASDAQ:ITUS) Thriving Or Barely Surviving In The Tech Sector?

    ITUS Corporation (NASDAQ:ITUS), is a $100.49M small-cap, which operates in the tech hardware industry based in United States. As various enterprises look to technology to enable their own transformations, theRead More...

  • ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26
    PR Newswire6 months ago

    ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26

    The presentation abstract titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," will be released on January 22nd, however the underlying data will be kept confidential until the presentation on January 26th.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology.

  • Who Are The Major Shareholders Of ITUS Corporation (NASDAQ:ITUS)?
    Simply Wall St.6 months ago

    Who Are The Major Shareholders Of ITUS Corporation (NASDAQ:ITUS)?

    I am going to take a deep dive into ITUS Corporation’s (NASDAQ:ITUS) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structure isRead More...

  • Is ITUS Corporation (NASDAQ:ITUS) Overpaying Its CEO?
    Simply Wall St.7 months ago

    Is ITUS Corporation (NASDAQ:ITUS) Overpaying Its CEO?

    Amit Kumar has been at the helm as CEO of ITUS Corporation (NASDAQ:ITUS), which has grown to a market capitalization of USD$44.54M. Recognizing whether CEO incentives are aligned with shareholdersRead More...

  • ITUS Corporation Terminates At-The-Market Offering
    PR Newswire7 months ago

    ITUS Corporation Terminates At-The-Market Offering

    SAN JOSE, Calif. , Dec. 12, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), announced today that it has terminated its at-the-market equity program ("ATM Offering") with B. Riley FBR, Inc.  ...